Global Nuclear Medicine Market Size To Worth USD 24.9 Billion by 2030 | CAGR of 13.8%Category: Healthcare
Global Nuclear Medicine Market To Worth $24.9 Billion by 2030
According to a research report published by Spherical Insights & Consulting, the Global Nuclear Medicine Market Size to grow from USD 9.2 Billion in 2021 to USD 24.9 Billion by 2030, at a Compound Annual Growth Rate (CAGR) of 13.8% during the forecast period.
Get more details on this report -
Browse key industry insights spread across 200 pages with 105 market data tables and figures & charts from the report on "Global Nuclear Medicine Market Size, Share, and COVID-19 Impact Analysis By Product (Diagnostics (SPECT, PET)), Therapeutics (Alpha Emitters, Beta Emitters, Brachytherapy), By Application (oncology, thyroid, neurology, cardiology, bone metastasis, lymphoma, endocrine tumors, and others), by Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2021 – 2030". Get Detailed Report Description Here: https://www.sphericalinsights.com/reports/nuclear-medicine-market
Radiopharmaceuticals are essentially pharmaceutical preparations that contain radioactive isotopes that are employed in therapeutic and diagnostic procedures. They are small, straightforward compounds with radioactive properties that are utilised to treat neurological, cancerous, and cardiac conditions. Convenient therapeutic radiopharmaceuticals are used instead of traditional chemotherapy techniques for oncology and cancer treatment, which creates new business opportunities for radiopharmaceuticals.
COVID 19 Impact
The COVID 19 pandemic has had a substantial influence on the healthcare sector, notably leading to a reduction in inpatient and outpatient services for illnesses and the implementation of infection control and prevention strategies. For instance, the COVID 19 influence on Europe has impacted nuclear medicine education in the majority of countries, according to the study released in June 2022.
The industry is being significantly boosted by the increase in the incidence and prevalence of cancer and cardiovascular illnesses. Nuclear medicine is crucial since the majority of these cases could have been averted with the aid of improved identification and treatment. As nuclear medicine aids in the diagnosis and treatment of diseases, the rising prevalence of various disorders is anticipated to propel the expansion of the global nuclear medicine market during the course of the forecast year. Nuclear medicine is used to diagnose cancer and cardiovascular disease. Additionally, radiopharmaceuticals' application domains are expanding as a result of which their market share and demand are anticipated to increase over the course of the projection year.
Players may use this symptom to their advantage by providing radiopharmaceuticals for neurological purposes, thereby diversifying their product offers and market positioning. Its short shelf lives, hospital spending limitations, and expensive equipment are anticipated to impede the market's expansion. The largest influence on a radiopharmaceutical's shelf life, however, comes from the radioisotope's half-life and the radionuclide's chemical composition. Radiochemical purity is poor when radioisotopes are not used within the recommended shelf life because to radiation and chemical deterioration. This could be lethal during the course of treatment and diagnosis.
The diagnostic product segment accounted the largest market share over the forecast period.
On the basis of product, the global nuclear medicine market is segmented into diagnostics, therapeutics. The diagnostics segment is further sub segmented into SPECT and PET. The therapeutics segment is further sub segmented into Alpha Emitters, Beta Emitters, Bracytherapy. Among these, the diagnostic product segment is dominating the market with the largest revenue share over the forecast period because there is a sizable patient population and cutting-edge technology like Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) are readily available. According to World Nuclear Association analysis, almost 40 million nuclear procedures are performed annually, and the need for radioisotopes continues to grow annually by about 5%. The market is also growing as a result of technological developments and a variety of radiotracers used in cancer screening.
The oncology segment is dominating the market over the forecast period.
Based on application, the global nuclear medicine market is segmented into oncology, thyroid, neurology, cardiology, bone metastasis, lymphoma, endocrine tumors, and others. Among these, the oncology segment is dominating the market and is going to continue its dominance over the forecast period. Due to various variables like smoking habits, an unhealthy diet, and a lack of exercise, many people worldwide are dying from cancer, which is driving the market's expansion. Increasing funding for nuclear medicine research and development for the treatment of cancer may also aid in the segment's expansion.
North America is dominating the market with the largest market share over the forecast period
Get more details on this report -
Due to its high volume of nuclear medicine techniques, sophisticated medical infrastructure, and increasing investment in research & development, North America will continue to dominate the market with the biggest market share over the projection period. For instance, Eckert & Ziegler announced in January 2021 their plans to build a cGMP facility in Boston, United States, for the contract production of radiopharmaceuticals.
On the other hand, Asia Pacific is expected to see the fastest market growth during the projected period as a result of rising interest in nuclear medicine therapies and rising investment in the sector. For instance, Penang Adventist Hospital (PAH) announced the opening of a private nuclear medicine centre in northern Malaysia in March 2022. The opening of this centre has had a favourable effect on the local economy.
Major vendors in the Global Nuclear Medicine Market include Mallinckrodt plc., General Electric Co. (healthcare division), Medtronic, Inc., Bayer AG, Cardinal Health, Inc., Lantheus Medical Imaging, Inc., and IBA Group.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global Nuclear Medicine Market based on the below-mentioned segments:
Nuclear Medicine Market, Product Analysis
- Diagnostic Products
- Therapeutic Products
Nuclear Medicine Market, End Use Analysis
- Bone Metastasis
- Endocrine Tumor
Nuclear Medicine Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: email@example.com, firstname.lastname@example.org
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?